Oral prostaglandin E2 in ductus-dependent pulmonary circulation

Area of Science:

• Neonatal Medicine
• Pediatric Cardiology
• Pharmacology

Background:

• Pulmonary circulation in neonates often relies on a patent ductus arteriosus.
• Prostaglandin E2 (PGE2) is crucial for maintaining ductus arteriosus patency.
• Intravenous (IV) PGE2 administration is established but poses challenges for long-term use.

Purpose of the Study:

• To evaluate the efficacy and safety of oral Prostaglandin E2 (PGE2) administration in neonates.
• To assess the impact of oral PGE2 on oxygen saturation and ductus arteriosus patency.
• To compare oral PGE2 administration with traditional IV methods for long-term treatment.

Main Methods:

• Oral PGE2 was administered to 12 neonates dependent on ductus arteriosus patency.
• Doses ranged from 12-65 microgram/kg at 1-4 hour intervals.
• Oxygen saturation (SaO2) and plasma PGE2 levels were monitored post-administration.

Main Results:

• Oral PGE2 consistently increased SaO2 and plasma PGE2 levels within 15-30 minutes.
• Treatment duration varied from 5 days to 4 months.
• PGE2 withdrawal led to a significant decrease in SaO2 in 8 infants.
• The ductus arteriosus remained responsive to PGE2 for extended periods (over 3 months in 4 infants).
• Side effects were similar to IV administration but less severe.

Conclusions:

• Oral PGE2 is an effective and simpler alternative to IV administration for maintaining ductus arteriosus patency in neonates.
• Oral PGE2 facilitates delayed surgical intervention, allowing for infant growth and pulmonary artery development.
• The reduced severity of side effects and ease of administration make oral PGE2 suitable for long-term therapy.